Encompass Health Corp Q3 FY2026 earnings call

• Financial Performance: Revenue grew 8.9% in Q3, driven by 5.7% discharge growth and a 4% increase in net revenue per discharge. Adjusted EBITDA increased 15.5% to $346.6 million, and adjusted EPS rose 23.6%. For the first nine months of 2026, revenue rose 9.2%, adjusted EBITDA increased 11.9%, and adjusted EPS was up 17%.
• Patient Outcomes & Quality: Discharge to community rate was 84.7%, exceeding industry averages. Encompass Health is recognized as America's most awarded leader in inpatient rehabilitation for the seventh consecutive year and received the 2026 NRC Health Excellence in Patient Experience Award. The company treats more stroke patients than any other IRF provider, comprising ~18% of its patient mix.
• Capacity Expansion: Opened four hospitals (189 beds) and added 85 beds to existing hospitals through Q3. Two additional 50-bed hospitals opened in Bangor, Maine, and San Antonio, Texas, with 60 additional beds added. A pipeline of 15 new hospitals (654 beds) exists beyond 2026, including two small-format hospitals in Texas. North Carolina’s repeal of certificate of need laws has created opportunities, with six real estate parcels under contract.
• Labor Efficiency: Premium labor costs declined $3.9 million year-over-year, marking 16 consecutive quarters of reduction. Contract labor FTEs are at 0.9%, the lowest since Q4 2020. Turnover was 20.7% in Q3, well below historical averages (~24%).
• Strategic Initiatives: Launched an Admit and Appeal Strategy for Medicare Advantage patients, resulting in an 87% overturn rate for claims. Expanding this pilot to all hospitals for stroke, with brain injury and spine as next targets. VA penetration continues to grow, hitting 21% growth in Q3.

The transcript does not provide a breakdown of financial performance by specific product segment or their respective revenue contribution percentages. The company operates primarily as a single inpatient rehabilitation facility (IRF) provider, with revenue driven by overall discharge growth and net revenue per discharge.

• Revenue: Raised full-year 2026 net operating revenue guidance to $6.45–$6.5 billion.
• Adjusted EBITDA: Raised full-year 2026 adjusted EBITDA guidance to $1.395–$1.415 billion.
• Adjusted EPS: Raised full-year 2026 adjusted earnings per share guidance to $6.23–$6.37.
• Net Provider Taxes: Lowered expectation for 2026 net contribution from net provider taxes to approximately $3 million (down from prior estimate of ~$10 million) due to pending CMS approval of Florida’s Medicaid State Directed Payment Program and related accrual reversals.
• Pre-opening Costs: Increased expectation for 2026 net pre-opening and ramp-up costs to $20–$24 million (up from prior run-rate), reflecting current incurrence and projections.

• Regulatory & Payer Risk: Expansion of Recovery Audit Contractor (RCD) programs to 75 additional hospitals in January 2027 raises concerns about administrative capacity at Palmetto GBA and potential bad debt volatility during Cycle 1 (100% prepayment review). Uncertainty remains regarding CMS approval of Florida’s Medicaid supplemental payment waivers.
• Operational Execution: One-time billing disruption following a system conversion in Q2 caused elevated bad debt expense (2.7% vs. historical 2–2.5%), though expected to normalize. Capacity constraints in high-occupancy hospitals (>90%) may limit same-store discharge growth until bed additions are completed.
• Market Dynamics: Potential slowdown in pricing growth if acuity trends plateau or if Medicare Advantage pre-authorization denials revert. Competitive pressures in Team Markets affecting lower-acuity procedures like joint replacements.

Q: What are the key headwinds and tailwinds for 2027, particularly regarding provider taxes, labor, and managed care pricing? / A: Doug Coltharp noted that 2027 should see upside from normalized provider tax accruals, avoiding previous one-off adjustments. Labor costs will face diminishing returns on premium pay reductions but remain manageable. Managed care pricing assumptions were raised 125 bps to 3.5–4%, driven by higher patient acuity and strong BACCN volume growth (>20%), which pays at fee-for-service rates. Medicare Advantage acuity increased due to stricter pre-authorizations, shifting the mix toward higher-value stroke patients.

Q: How is the company addressing capacity constraints, and what is the strategy for small-format hospitals? / A: Approximately 58 hospitals operate above 90% occupancy, with 19 receiving bed additions by end of FY2027. Small-format hospitals (e.g., Conroe and Richmond, TX) are being piloted to address physical limitations in dense markets. These projects target a 20% IRR with ~$1 million cost per bed, leveraging shared admin staff with host hospitals. Regulatory permitting challenges have slowed initial rollout, but the team expects to accelerate deployment to 6+ units annually by 2028–2029 once licensing templates are established.

Q: What is the impact and scalability of the Medicare Advantage Admit and Appeal Strategy? / A: Pat Tuer highlighted that the pilot program, initially covering 9 hospitals, achieved an 87% claim overturn rate, with 81% resolved before Administrative Law Judges. In pilot markets, MA discharge growth reached 9.3%, significantly outperforming the broader MA decline of 1.1%. The strategy is now expanding to all hospitals for stroke patients, with plans to scale to brain injury and spine. This initiative helps counteract rising MA pre-authorization denials and improves referral source relationships.

Q: How is the expansion of RCD programs impacting operations and bad debt expectations? / A: With RCD expanding to 75 more hospitals, management expressed concern over Palmetto GBA’s ability to handle a 10x volume increase. However, they maintain high confidence in meeting the 80% affirmation rate target in Cycle 1, which would allow a shift to 5% spot checks by July 2027. Bad debt is expected to remain within the historical 2–2.5% range, as admission criteria have not changed. Any short-term volatility is anticipated to be contained to the first half of 2027.

Q: What are the capital allocation priorities given the low leverage ratio of 1.8x? / A: Management indicated that while dividends may see modest increases, the primary focus will be discretionary capital expenditure to support an accelerating pipeline of de novo and small-format hospital openings, particularly in attractive markets like North Carolina. Share repurchases will continue but are secondary to capacity expansion. The company aims to maintain favorable leverage while investing in growth, viewing share buybacks as opportunistic rather than mandatory at current levels.